Merrill has Acambis at neutral

Acambis plc was rated at neutral by Merrill Lynch analyst Erica Whittaker following publication of documents from the ongoing smallpox vaccine patent litigation between Bavarian Nordic and Acambis. A ruling is expected by the end of August. Both companies are expected to be awarded government contracts to produce vaccine doses. Shares of the Cambridge, England-based pharmaceutical company were up 2p, or 1.14%, at 178p on volume of 1,849,218 shares versus the three-month running average of 489,124 shares. (London: ACM)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.